Background: There is a paucity of data on the prognostic impact of thyroid dysfunction in patients with heart failure (HF). We aimed to examine the association between these 2 conditions in a nationwide cohort of patients with HF.
Methods: This Danish cohort study evaluated the thyroid function of patients diagnosed with first-time HF from 2000-2021. Patients were categorized according to laboratory-based thyroid-function values (euthyroid, overt/subclinical hypothyroidism or hyperthyroidism) recorded within 1 year before the HF diagnoses. The primary outcome was a composite of mortality and hospitalization due to HF, examined using the cumulative incidence function. Cox proportional hazard analysis adjusted for major comorbidities was performed to investigate differences in outcomes among groups.
Results: Of the 58,067 individuals included in this study (43.9% female, median age 75.7 years [p25-p75:66.4-83.5]), 54,319 (93.6%) were euthyroid, 1669 (2.9%) had subclinical hypothyroidism, 239 (0.4%) had overt hypothyroidism, 1633 (2.8%) had subclinical hyperthyroidism, and 207 (0.4%) had overt hyperthyroidism. Compared with euthyroid patients, the adjusted 1-year HR of the composite outcome was 1.11 (95% CI, 1.02-1.20) in patients with subclinical hypothyroidism, 1.24 (95% CI, 1.02-1.51) in patients with overt hypothyroidism, 1.06 (95% CI, 0.98-1.15) in patients with subclinical hyperthyroidism, and 1.27 (95% CI, 1.00-1.60) in patients with overt hyperthyroidism. This positive association was driven mainly by the increased mortality rates.
Conclusion: In patients with incident HF, the presence of both hypo- and hyperthyroidism up to 1 year prior to HF diagnosis was associated with increased risk of the composite of mortality and hospitalization for HF. Our results demonstrate a high-risk group of patients in need of increased clinical awareness.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cardfail.2024.11.010 | DOI Listing |
Lung Cancer
January 2025
Dept. of Medical Oncology, Princess Margaret Cancer Center, Toronto, ON, Canada.
Background: Manual extraction of real-world clinical data for research can be time-consuming and prone to error. We assessed the feasibility of using natural language processing (NLP), an AI technique, to automate data extraction for patients with advanced lung cancer (aLC). We assessed the external validity of our NLP-extracted data by comparing our findings to those reported in the literature.
View Article and Find Full Text PDFLung Cancer
January 2025
Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Objectives: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC through comprehensive gene expression analysis using machine learning (ML).
Methods: A prospective multicenter cohort of patients with ES-SCLC who received first-line chemo-immunotherapy was analyzed.
J Geriatr Oncol
January 2025
Hellenic Oncology Research Group (HORG), 55, Lomvardou str, 11470 Athens, Greece.
Introduction: The use of taxanes in the adjuvant setting of early breast cancer (BC) confers survival benefits, however, their role in older patients merits further study. This retrospective pooled analysis of randomized controlled trials conducted by the Hellenic Oncology Research Group (HORG) aims to assess the efficacy and safety of taxane-based adjuvant chemotherapy in older women with BC.
Materials And Methods: Five phase III trials containing a taxane, conducted by HORG between 1995 and 2013, were included in a patient-data pooled analysis.
Drug Metab Pharmacokinet
November 2024
Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.
View Article and Find Full Text PDFActa Pharm
December 2024
Department of Clinical Pharmacy, University Hospital Dubrava, 10000 Zagreb Croatia.
Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally. It is estimated that 17.9 million people died from CVDs in 2019, which represents 32 % of all deaths worldwide.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!